

1 **Long-term effects of directional deep brain stimulation in Parkinson's**
2 **disease: a randomized clinical trial on motor and non-motor**
3 **symptoms**

4 Gharabaghi A^{1,2,3*}, Cebi I^{1,4}, Scherer M^{1,5}, Bookjans P¹, Brunnett B¹, Milosevic L^{1,5}, Weiss D⁴

5

6 1. Institute for Neuromodulation and Neurotechnology, University Hospital and
7 University of Tübingen, 72076 Tübingen, Germany

8 2. Center for Bionic Intelligence Tübingen Stuttgart (BITS), 72076 Tübingen, Germany

9 3. German Center for Mental Health (DZPG), 72076 Tübingen, Germany

10 4. Center for Neurology, Department for Neurodegenerative Diseases, and Hertie
11 Institute for Clinical Brain Research, University Tübingen, 72076 Tübingen, Germany

12 5. Clinical and Computational Neuroscience, Krembil Research Institute, University
13 Health Network, M5T 2S8 11 Toronto, Canada.

14

15 *Corresponding author: Prof. Alireza Gharabaghi. Address: Institute for
16 Neuromodulation and Neurotechnology, University Hospital Tübingen, Otfried-Müller-
17 Str. 45, 72076 Tübingen, Germany. Email: alireza.gharabaghi@uni-tuebingen.de

18

19 Key words: Deep brain stimulation; directional steering; segmented contacts; ring
20 contacts; circular contacts; long-term effects.

21

22 **Abstract**

23 Background

24 Deep brain stimulation (DBS) of the subthalamic nucleus (STN) in Parkinson's disease
25 (PD) that is more precisely focused to the desired target structure may avoid nearby
26 structures that are responsible for undesired side effects.

27 Objective

28 Comparing the long-term effects of STN-DBS with segmented or ring contacts on motor
29 and non-motor symptoms in akinetic-rigid PD patients.

30 Methods

31 This study was a prospective randomized clinical trial. At 6-months postoperatively, the
32 optimal omnidirectional (OS) and directional (DS) stimulation contacts were compared
33 in MedOFF within a double-blind cross-over design, both acutely (within one day) and
34 chronically, i.e., after 3-week stimulation blocks of each condition. The examination
35 included motor and non-motor evaluations (e.g., cognition, mood and quality of life).
36 Importantly, the stimulation intensity of the optimal DS was adjusted such that the total
37 electrical energy delivered (TEED) was equivalent to the TEED of the optimal OS.

38 Results

39 There were no significant differences between OS and DS with regard to all outcome
40 parameters, with 30% less stimulation intensity of the latter. Notably, OS scored (non-
41 significantly) better than DS in all motor and non-motor measures apart from the
42 cognitive evaluation, where OS led to a deterioration of executive functions. However, in
43 3 of 19 patients, the stimulation intensity of DS needed to be increased above the
44 TEED-estimated values to reach the motor benefits of OS.

45 Conclusions

46 Reliable comparisons between OS and DS require long-term clinical evaluations. A
47 potential differential influence on motor and non-motor symptoms needs to be
48 investigated in future confirmatory studies.

49 Registration: ClinicalTrials.gov: NCT03548506

50 Introduction

51 Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an evidence-based
52 and cost-effective therapy for idiopathic Parkinson's disease (PD) patients, with superior
53 motor, non-motor and quality of life outcomes compared to the best medical therapy
54 once dopaminergic response fluctuations occur (1-7). The greatest therapeutic
55 effectiveness of DBS is often achieved in the motor part of the STN and its immediate
56 surrounding (8). However, the spread of the stimulation current into nearby structures
57 can also lead to side effects such as muscle contractions, paresthesia, postural
58 instability, speech impairment, reduced verbal fluency, involuntary eye movements, and
59 impaired cognition (9-11). Among them, motor-related side effects (e.g., muscle
60 contractions) are usually immediately detected and can often be addressed with
61 adjusting the stimulation parameters. However, when they occur at low stimulation
62 intensities, which are insufficient to achieve the therapeutic benefits, and when
63 reprogramming cannot resolve the condition, subsequent surgery for lead revision may
64 be necessary (12). In contrast, non-motor side effects (e.g., cognitive impairment) are
65 often less apparent and remain undetected, when searching for optimal stimulation
66 parameters in the acute setting.

67 Technological progress of the implanted stimulation hardware has raised new hope to
68 overcome current limitations. Specifically, in the new generation of electrodes, the
69 middle two of the usually four ring contacts are divided into three segments each. This
70 makes it possible, in addition to circular/omnidirectional stimulation (OS) in the
71 conventional ring mode, to also focus the stimulation field more precisely in the
72 horizontal plane around one or two electrode segments with directional stimulation
73 steering (DS). In this context, previous studies have investigated, both intraoperatively
74 (13, 14) and extraoperatively (7, 15-17), the therapeutic windows of DS and OS, i.e., the
75 range between the stimulation amplitude that first produces beneficial effects and the
76 stimulation amplitude that first produces side effects. An increased therapeutic window
77 of DS vs. OS has often been reported during these acute evaluations, thus suggesting
78 that DS away from the structures causing side effects is in principle possible. Whether
79 these gains are also clinically relevant in the long-term, e.g., by compensating for

80 suboptimal electrode placements and reducing the necessity for revision surgery, is still
81 an open question. Despite a considerable evolution of image-guided neurosurgical
82 targeting methods (18, 19), refined intraoperative techniques (20, 21), awake
83 procedures (22) and novel stimulation paradigms (23), the side effects and/or
84 insufficient therapeutic benefits may lead to revision surgery in up to 15-30% of patients
85 (12). A simulation study, for example, suggests that DS reduces out-of-target
86 stimulation (that would lead to side effects), but is limited in achieving the target volume
87 (for maximum therapeutic benefit), when compensating for suboptimal electrode
88 placements with a shift of more than 1 mm (24). Moreover, a recent study revealed that
89 six of 42 patients (i.e., ten of 72 leads) required surgical revision owing to electrode
90 malposition despite the ability to steer the current with DS to relieve stimulation-induced
91 side effects (25). This may suggest that the frequently described improvements in
92 surrogate parameters such as the therapeutic window do not regularly translate into
93 clinical benefits (26).

94 On this basis, it is of particular relevance to determine the potential of DS to improve the
95 therapeutic precision in the majority of patients with well-placed electrode leads where
96 beneficial therapeutic effects can be achieved without acute side effects. For these
97 cases, it is unknown as to whether DS allows for a more efficient stimulation of the
98 target structure, e.g., by lowering the stimulation intensity required to achieve the
99 desired clinical benefit, also for longer observation periods beyond acute assessments.
100 Such long-term assessments would allow to estimate potential benefits of DS also with
101 regard to non-motor side effects, e.g., cognitive impairment.

102 In this context, an important consideration is that therapeutic impedance and surface
103 current density are dependent on the electrode surface, and systematically differ
104 between larger ring and smaller segmented contact sizes; associated with greater
105 current density of the latter (27). It has therefore been suggested that stimulation
106 intensity adjustments using DS should be performed using smaller amplitude
107 increments (i.e., 0.1–0.3 mA compared to the traditional 0.5 mA). Moreover, it needs to
108 be considered that because of the higher impedance (1.8-2.2 times that of standard ring
109 contacts) due to the smaller stimulating surface of segmented contacts, stimulation at a

110 particular intensity is associated with a greater total electrical energy delivered (TEED)
111 when using DS compared to OS. As such, these settings would impose a greater
112 energy burden and quicken battery consumption; which is an important factor
113 influencing the frequency of subsequent surgical procedures for battery replacement.
114 Already an 18% increase from the average TEED with DS vs. OS, would lead to as
115 much as a year of battery lifespan lost ⁴⁵. Therefore, the desired stimulation effects need
116 to be achieved with at least the same TEED, i.e., about 30% lower stimulation
117 amplitudes of DS vs. OS, to avoid a negative influence on the battery lifespan (28).
118 These aspects need to be considered when aiming for overall improvements of clinical
119 care. Moreover, the stimulation effects in previous studies were only recorded clinically
120 using an ordinal scale (i.e., the Unified Parkinson's Disease Ratings Scale; UPDRS)
121 and were therefore dependent on subjective assessments of the symptoms.


122 We have therefore designed a study to systematically compare the efficacy of DS vs.
123 OS in the context of a prospective, randomized, double-blind, crossover clinical trial,
124 taking the aforementioned considerations into account. Namely, (i) applying – in
125 addition to clinical measures - also an objective and ratio-scaled measure, i.e.,
126 electromyography (EMG) (29) to assess muscular rigidity; (ii) conducting stimulation
127 titration at each contact with small increments in stimulation intensity (0.2 mA steps) for
128 both stimulation conditions; (iii) maintaining TEED between DS and OS; (iv) applying
129 the randomized, double-blinded evaluations after both acute *and* chronic stimulation
130 periods; and (v) assessing both motor *and* non-motor symptoms. We tested the
131 hypothesis that, even under these rigorously controlled conditions, the focused
132 stimulation of the target structure with DS could achieve similar therapeutic efficacy on
133 motor symptoms while reducing non-motor side effects.

134

135 **Methods**

136 **Patients**

137 All patients who participated in this study were nominated for deep brain stimulation
138 surgery upon multidisciplinary review based on standard inclusion/exclusion criteria for
139 STN-DBS in PD (30), independent from study participation. The study was approved by
140 the ethics committee of the Medical Faculty of the University of Tuebingen. Twenty-
141 three consecutive akinetic-rigid patients scheduled for STN-DBS were included in this
142 study after providing written informed consent to participation. Four patients dropped out
143 due to personal reasons not related to the study. Nine-teen patients completed the
144 study with the cross-over treatment evaluation periods. Participant and drop-out
145 numbers at each phase of the study are summarized in Figure. 1. Patient demographics
146 are summarized in Table 1.



147

148 *Figure 1: Consort flow diagram of the SANTOP study*

ID	Sex/ gender	Age (years)	Disease duration (years)	LEED (mg/d)	Stimulation parameters Omnidirectional	Stimulation parameters Directional
1	m	60s	10-15	1000-1250	L 3- G+ 2.1mA 60µs 130Hz R 11- G+ 3.7mA 60µs 130Hz	L 3C- G+ 1.4mA 60µs 130Hz R 11B- G+ 2.3mA 60µs 130Hz
2*	f	60s	10-15	750-1000	L 3- G+ 3.3mA 60µs 130Hz R 11- G+ 3.5mA 60µs 130Hz	L 3A- G+ 2.5mA 60µs 130Hz R 11C- G+ 2.5mA 60µs 130Hz
3	m	50s	10-15	1000-1250	L 3- G+ 1.3mA 60µs 130Hz R 11- G+ 2.3mA 60µs 130Hz	L 3C- G+ 0.5mA 60µs 130Hz R 11A- G+ 1.2mA 60µs 130Hz
4*	m	70s	10-15	250-500	L 3- G+ 2.70mA 60µs 130Hz R 11- G+ 2.20mA 60µs 130Hz	L 3A- G+ 2.2mA 60µs 130Hz R 11A- G+ 2.0mA 60µs 130Hz
5	m	50s	5-10	1000-1250	L 3- G+ 1.5mA 60µs 130Hz R 11- G+ 1.5mA 60µs 130Hz	L 3A- G+ 0.95mA 60µs 130Hz R 11C- G+ 1.05mA 60µs 130Hz
6	m	50s	5-10	1250-1500	L 3- G+ 0.8mA 60µs 130Hz R 11- G+ 4.5mA 60µs 130Hz	L 3A- G+ 0.55mA 60µs 130Hz R 11A- G+ 3.1mA 60µs 130Hz
7	m	40s	10-15	1250-1500	L 3- G+ 1.6mA 60µs 130Hz R 11- G+ 3.7mA 60µs 130Hz	L 3A- G+ 1.25mA 60µs 130Hz R 11B- G+ 2.85mA 60µs 130Hz
8*	f	60s	10-15	750-1000	L 3- G+ 2.2mA 60µs 130Hz R 11- G+ 4.0mA 60µs 130Hz	L 3A- G+ 1.8mA 60µs 130Hz R 11C- G+ 2.7mA 60µs 130Hz
9	f	50	10-15	250-500	L 3- G+ 2.8mA 60µs 130Hz R 11- G+ 2.9mA 60µs 130Hz	L 3A- G+ 2.05mA 60µs 130Hz R 11B- G+ 1.95mA 60µs 130Hz
10	f	70s	10-15	500-750	L 3- G+ 4.7mA 60µs 130Hz R 11- G+ 4.7mA 60µs 130Hz	L 3B- G+ 3.35mA 60µs 130Hz R 11B- G+ 3.35mA 60µs 130Hz
11	f	50s	15-20	500-750	L 3- G+ 1.1mA 60µs 130Hz R 11- G+ 1.5mA 60µs 130Hz	L 3B- G+ 0.75mA 60µs 130Hz R 11C- G+ 1.00mA 60µs 130Hz
12	m	60s	5-10	250-500	L 3- G+ 2.7mA 60µs 130Hz R 11- G+ 2.8mA 60µs 130Hz	L 3C- G+ 2.6mA 60µs 130Hz R 11A- G+ 1.95mA 60µs 130Hz
13	m	70s	10-15	1000-1250	L 3- G+ 2.5mA 60µs 130Hz R 11- G+ 2.7mA 60µs 130Hz	L 3B- G+ 1.7mA 60µs 130Hz R 11B- G+ 1.85mA 60µs 130Hz
14	m	70s	5-10	750-1000	L 3- G+ 3.0mA 60µs 130Hz R 11- G+ 2.8mA 60µs 130Hz	L 3C- G+ 2.1mA 60µs 130Hz R 11A- G+ 1.8mA 60µs 130Hz
15	m	60s	10-15	750-1000	L 2- G+ 1.7mA 60µs 130Hz R 10- G+ 2.2mA 60µs 130Hz	L 2C- G+ 1.1mA 60µs 130Hz R 10B- G+ 1.4mA 60µs 130Hz
16	m	60s	15-20	750-1000	L 3- G+ 2.8mA 60µs 130Hz R 11- G+ 3.3mA 60µs 130Hz	L 3B- G+ 2.1mA 60µs 130Hz R 11B- G+ 2.3mA 60µs 130Hz
17	f	50s	5-10	500-750	L 3- G+ 2.3mA 60µs 130Hz R 11- G+ 2.1mA 60µs 130Hz	L 3C- G+ 1.65mA 60µs 130Hz R 11C- G+ 1.5mA 60µs 130Hz
18	m	50s	5-10	750-1000	L 3- G+ 2.7mA 60µs 130Hz R 11- G+ 0.9mA 60µs 130Hz	L 3A- G+ 1.9mA 60µs 130Hz R 11B- G+ 0.5mA 60µs 130Hz
19	m	60s	10-15	1000-1250	L 3- G+ 2.7mA 60µs 130Hz R 11- G+ 2.5mA 60µs 130Hz	L 3C- G+ 1.8mA 60µs 130Hz R 11C- G+ 1.7mA 60µs 130Hz

149

150 *Table 1: Patient demographics and stimulation parameters are summarized in. LEED*
151 *indicates the levodopa equivalent dose during the cross-over-phase. The asterisk “*”*
152 *indicates patients in whom a reprogramming was necessary during the cross-over-*
153 *phase: ID2: the calculated directional stimulation was L 3A- G+ 2.1mA 60µs 130Hz, R*

152 11C- G+ 2.2mA 60 μ s 130Hz; patient reported bradykinesia and had rigidity and freezing
153 of gait with directional stimulation during the cross-over-phase so that we needed to
154 increase the stimulation Intensity.

155 ID4: the calculated directional stimulation was L 3A- G+ 1.85mA 60 μ s 130Hz, R 11A-
156 G+ 1.55mA 60 μ s 130Hz; patient reported bradykinesia and had rigidity with directional
157 stimulation during the cross-over-phase so that we needed to increase the stimulation
158 intensity.

159 ID8: the calculated directional stimulation was L 3A- G+ 1.6mA 60 μ s 130Hz, R 11C- G+
160 2.6mA 60 μ s 130Hz; patient reported worsening of motor fluctuations so that we needed
161 to increase the stimulation intensity.

162

163 **Surgical procedure**

164 The tentative implantation location in each hemisphere was initially determined by
165 conventional image-based direct targeting of the STN using preoperative MRI (T2-
166 weighted and/or SWI) (31). Patients were withdrawn from antiparkinsonian medications
167 overnight, and on the day of surgery electrophysiological recordings of single-unit
168 and/or local field potential activities were used to confirm the target location in each
169 hemisphere. Initially, single unit recordings were used to delineate STN entry and
170 spatial extent by characteristic burst firing rates (20-60 Hz) and irregular or bursting
171 patterns (32). The trajectory yielding greatest spatial extent of STN was then selected
172 for the DBS electrode implant. The final position of the DBS electrode was once again
173 titrated using neurophysiological recordings directly from the DBS contacts, such that
174 two levels of the DBS lead containing segmented contacts were placed in the area of
175 STN yielding greatest beta (13-30 Hz) oscillatory power, determined by (online)
176 intraoperative power spectral density calculations (21). There were no complications
177 from surgical procedures.

178 **Study design**

179 This study was a prospective, randomized, double-blind, crossover, single-center
180 clinical trial, i.e., the SANTOP (Subthalamic steering for therapy optimization in
181 Parkinson's Disease) study (preregistered at ClinicalTrials.gov: NCT03548506). The

182 comprehensive study design is illustrated as Figure 1. The patients were enrolled
183 preoperatively (V0). The postoperative visits started 2-months (V1/2) and 6-months
184 (V3/4/5) after surgery. All evaluations were done in the Med OFF condition after
185 overnight withdrawal of dopaminergic medication. The patients and the evaluators were
186 blinded to stimulation conditions during the whole study. At the 2-months visits, a
187 monopolar review was performed on two subsequent days to identify the optimal
188 contact and stimulation parameters for omnidirectional (V1) and directional (V2)
189 stimulation.

190 At the 6-months visit (V3), OS and DS were compared to each other and to Stim OFF in
191 randomized order, i.e., 30 minutes from reprogramming for each condition (acute
192 setting). Afterwards, stimulation settings were randomized again for a three-week
193 (chronic setting) active treatment period (by a study coordinator who would not be
194 involved in clinical evaluation) to either the omnidirectional settings, or the energy-
195 equivalent directional settings (preconfigured options in the stimulation programmer).
196 After the first three-week treatment period (V4), blinded collection of outcome data
197 (described below) was performed by a clinician, followed by a cross-over in stimulation
198 settings performed by a study coordinator. After another 3-week treatment period (V5),
199 blinded outcome data were collected once more. This procedure allowed to directly
200 compare OS and DS after long-term stimulation periods, during which other parameters
201 (such as medication) were kept unchanged. These study epochs are summarized in
202 Figure 1.

203 ***Identification of optimal contact and stimulation parameters***

204 At 2-months (on average 67 days, +/- 9 days, range 56-88 days) postoperatively (see
205 Figure 1), stimulation titration was performed on two subsequent days after overnight
206 withdrawal from medication. On the first day (V1), each patient underwent a monopolar
207 review of the three upper contacts using circular stimulation at each level to determine
208 the optimal OS level. On the second day (V2), the same procedure was repeated using
209 the three segmented contacts of the previously determined best omnidirectional level
210 (V1) to determine the optimal stimulation direction.

211 During these visits, rigidity in the contralateral upper limb was assessed (double-blind)
212 by a clinician during unilateral stimulation, while the programming and random electrode
213 contact selection was conducted by another examiner at a stimulation frequency of
214 130 Hz and a pulse width 60 μ s, using intensities starting from 0.5 mA and
215 incrementally increasing by 0.2 mA, until a (self-reported) side effect threshold was
216 reached. At each stimulation increment, a 1-minute rigidity assessment (consisting of
217 passive movements of the upper limb by flexing and extending the elbow) was
218 performed to determine the effect threshold.

219 The therapeutic window was determined for each evaluated contact, and the contact
220 with the greatest therapeutic window and/or best effect threshold in each hemisphere
221 was considered optimal. The stimulation intensity for each optimal segmented contact
222 was then determined by titration of the stimulation intensity such that the total electrical
223 energy delivered (33) was equivalent to the total electrical energy of the optimal
224 omnidirectional settings. Of note, the stimulation intensity for DS was always lower than
225 for OS due to the greater impedance associated with a smaller stimulation surface (see
226 also the Introduction). The OS and DS parameters for each patient are available in
227 Table 1.

228 ***Treatment evaluation and outcome measures***

229 At a minimum of 6-months (on average 229 days, +/- 46 days, range 187-369 days)
230 postoperatively (see Figure 1), OS and DS were compared to each other in an acute
231 (V3) and chronic setting (V4/5). The muscle rigidity of the upper extremity was
232 measured by means of surface EMG recording (BrainAmp DC/EXG, Brain Products,
233 Munich, Germany; sampled at 5 kHz) of the M. biceps brachii and the M. triceps brachii.
234 Previous work suggests that the EMG profile during standardized passive extension and
235 flexion movements of the elbow joint is influenced by DBS and corresponds with
236 standardized clinical scales (29). The evaluation procedure consisted of EMG recording
237 during a 30-second non-movement period, followed by a 60-second period of passive
238 flexion/extension (~0.5 Hz cycles) of the elbow (~90°). Five trials of this procedure were
239 performed for each arm at each stimulation intensity and each electrode contact.

240 At both V3 and V4/5, the following data was collected: MDS-UPDRS parts III (34); timed
241 Capsit-PD walking test (35); Freezing of Gait Assessment Course (FoG-AC) (36);
242 Spatial (SDR) (37) and verbal (VDR) (38) working memory with respective visual (39)
243 and acoustic odd-ball tests (40) for attention monitoring, and task-related EEG
244 recordings (41). During the acute V3 assessment, no stimulation (STIM OFF),
245 directional and omnidirectional settings were compared in randomized order. During the
246 chronic V4/5 cross-over assessment, directional and omnidirectional settings were
247 compared in randomized order.

248 At V4/5, this additional data was acquired: MDS-UPDRS part I, II and IV (34);
249 Parkinson's Disease Quality of Life Scale (PDQ-39) (42); Becks 'Depression Inventory
250 (BDI) (43); Montreal Cognitive Assessment (MoCA) (44); Apathy Scale (45); Lille
251 Apathy rating scale (46); Deep Brain Stimulation impairment scale (DBS-IS) (47).

252 ***EMG data processing and analysis***

253 EMG data processing consisted of artifact rejection, epoching, feature extraction and,
254 faulty trial rejection. Initially, the stimulation artifact, the line noise, and their respective
255 harmonics were removed from the data. After artifacts had been removed, the data
256 were split into epochs. From each run, two segments were extracted, a 30-second non-
257 movement segment and a 30-second movement segment. These segments were
258 further divided into individual 2-second epochs. While strict 2-second cutting was
259 applied to the non-movement phase data, the movement phase data were cut according
260 to full movement cycles (0.5 Hz). To extract feature information from the EMG signal,
261 the signal was detrended, and enveloped via the absolute of the Hilbert transform. The
262 average amplitude (power) of the signal was extracted as feature information and was
263 then normalized with respect to the overall EMG power between 2 and 300 Hz to
264 account for different impedance levels across recordings. Finally, outliers on a feature
265 level were rejected if z-score > 2 (i.e., more than two standard deviations from the
266 mean).

267 EMG data was analyzed using generalized linear mixed models (glmm). Factors
268 modeled in the analysis were as follows: "counter-movement" to evaluate the effect of
269 the counter-movement on the EMG power; the "stimulation-condition:" to contrast DS

270 and OS modes; “movement” to contrast between rest versus passive movement phases
271 in EMG activity; the interaction between the stimulation-condition and movement; the
272 (chronologically ordered) “recording id” to compensate for repeated measurements over
273 time; “trial id” to compensate for repeated measurements within trials; “patient id” as a
274 random factor to compensate for repeated measurements across patients. Secondary
275 outcome data of standardized clinical score assessments were assessed using paired
276 Wilcoxon signed-rank tests to compare stimulation conditions.

277 Results

278 At 6-months postoperatively, optimal ring and segmented contacts were compared to
 279 each other with average TEED-adapted stimulation intensities of 2.59 ± 0.77 mA for OS
 280 and 1.82 ± 0.61 mA for DS; this was equivalent to a difference of 30.37 ± 8.47 %. First,
 281 OS and DS were compared to each other and to Stim OFF in randomized, cross-over
 282 order in an acute setting (V3), i.e., 30 min after reprogramming within the same day.
 283 After this acute assessment, OS and DS were compared to each other in randomized,
 284 cross-over order in a chronic/long-term setting, i.e., 3 weeks after reprogramming for
 285 each condition (V4/5).

286 Motor symptoms

287 In the *acute setting* (V3), both conditions had similar therapeutic efficacy on motor
 288 symptoms, i.e., there was no significant difference between OS and DS (Table 2).
 289 Specifically, OS (30.00 ± 13.55 ; $p=.001$) and DS (30.72 ± 10.87 ; $p=.003$) improved
 290 UPDRS III as compared to Stim OFF (39.63 ± 12.92); also, the FoG-AC improved with
 291 both OS (14.83 ± 13.66 ; $p=.021$) and DS (13.92 ± 13.32 ; $p=.024$) as compared to Stim
 292 OFF (17.83 ± 15.05). There were, however, no significant differences between OS and
 293 DS for UPDRS III ($p=.521$) and FoG-AC ($p=.591$), or the other outcome measures
 294 including the oddball and working memory tasks (VDR/SDR).

	Scores			Wilcoxon signed-rank test								
	Omnidirectional	Directional	Stim Off	Stim Off vs Omnidirectional			Stim Off vs Directional			Omnidirectional vs Directional		
	Mean \pm SD/ Median [min max]	Mean \pm SD/ Median [min max]	Mean \pm SD/ Median [min max]	p-value	z-value	n	p-value	z-value	n	p-value	z-value	n
MDS-UPDRS III	30.00 \pm 13.55	30.72 \pm 10.87	39.63 \pm 12.92	0.001	-3.298	15	0.003	-2.985	15	0.521	-0.641	17
VDR												
Task accuracy	0.71 \pm 0.27	0.69 \pm 0.27	0.65 \pm 0.31	0.181	-1.338	15	0.440	-0.772	16	0.860	-0.176	16
Task reaction time	2.56 \pm 0.63	2.51 \pm 0.59	2.56 \pm 0.38	0.379	-0.879	14	0.532	-0.625	15	0.925	-0.094	15
Oddball accuracy	0.94 \pm 0.07	0.90 \pm 0.21	0.89 \pm 0.17	0.676	-0.418	15	1.000	0.000	16	0.324	-0.986	16
Oddball reaction time	0.92 \pm 0.23	0.90 \pm 0.26	1.18 \pm 0.51	0.061	-1.875	15	0.002	-3.131	16	0.227	-1.087	16
SDR												
Task accuracy	0.27 \pm 0.10	0.30 \pm 0.07	0.29 \pm 0.08	0.553	-0.593	15	0.288	-1.063	14	0.475	-0.714	15
Task reaction time	1.76 \pm 0.78	1.73 \pm 0.60	1.80 \pm 0.68	1.000	0.000	15	0.925	-0.094	14	0.532	-0.625	15
Oddball accuracy	0.64 \pm 0.22	0.64 \pm 0.21	0.65 \pm 0.23	0.864	-0.171	15	0.861	-0.175	14	0.527	-0.633	15
Oddball reaction time	1.04 \pm 0.41	1.04 \pm 0.34	1.11 \pm 0.42	0.826	-0.220	14	0.363	-0.910	14	0.875	-0.157	14
FoG-AC	14.83 \pm 13.66	13.92 \pm 13.32	17.83 \pm 15.05	0.021	-2.307	12	0.024	-2.251	12	0.591	-0.538	12
CAPSIT												
Steps	38.36 \pm 22.26	43.50 \pm 33.56	38.75 \pm 26.29	0.119	-1.561	12	0.285	-1.069	12	0.166	-1.385	14
Time (s)	33.07 \pm 43.95	37.86 \pm 58.97	37.58 \pm 51.46	0.073	-1.795	12	0.349	-0.936	12	0.244	-1.166	14
Freezing episodes	0.93 \pm 1.73	2.50 \pm 5.97	1.67 \pm 3.42	0.273	-1.095	12	1.000	0.000	12	0.225	-1.214	14

295

296 *Table 2: Six months after surgery (V3), both conditions (OS and DS) had significant*
297 *therapeutic efficacy with regard to segmental (MDS-UPDRS III) and axial motor (FOG-*
298 *AC) symptoms compared to Stim Off during the acute evaluation (i.e., 30 min*
299 *stimulation periods); however, there were no significant differences between the*
300 *omnidirectional (OS) and directional (DS) conditions.*

301 In the *long-term setting (V4/5)*, both conditions had also similar therapeutic efficacy, i.e.,
302 there were no significant differences between OS and DS with regard to motor
303 symptoms (Table 3) and EMG-based assessments ($p \geq .135$). However, in 3 of the 19
304 patients (i.e., 15.79%), stimulation amplitudes had to be increased for the DS condition
305 (above and beyond the estimated TEED) to achieve the therapeutic current strength,
306 i.e., to avoid motor fluctuations, bradykinesia, rigidity and freezing of gait (for further
307 details see the legend of Table 1).

308 Notably, OS scored (non-significantly) better than DS for UPDRS III (28.63 ± 12.91 vs.
309 32.42 ± 15.07), FoG (11.47 ± 13.02 vs. 12.80 ± 13.80), CAPSIT steps (39.11 ± 20.55
310 vs. 42.00 ± 22.02), CAPSIT time (27.44 ± 23.74 vs. 31.82 ± 34.04), and PDQ-39
311 Mobility (19.22 ± 10.73 vs. 21.13 ± 8.16). Moreover, long-term stimulation (i.e.,
312 evaluation after 3-week blocks, V4/5) changed the scores in comparison to the acute
313 evaluation (i.e., evaluation after 30 min, V3); specifically, the UPDRS III score improved
314 from 30.00 ± 13.55 to 28.63 ± 12.91 for OS, and deteriorated from 30.72 ± 10.87 to
315 32.42 ± 15.07 for DS.

316 ***Non-motor symptoms***

317 In the long-term setting (V4/5), there were no significant differences between OS and
318 DS with regard to non-motor symptoms (Table 3). Notably, OS scored (non-
319 significantly) better than DS on all (BDI, AS, DBS-IS, LARS, PDQ-39) but one non-
320 motor clinical measure. The only non-motor clinical measure favoring DS was the
321 MOCA evaluation; specifically, OS led to (non-significantly) more cognitive impairment,
322 i.e., a lower MOCA score as compared to DS (26.53 ± 3.15 vs. 27.83 ± 1.92 ; $p=.080$).
323 This effect was driven by a deterioration of the MOCA sub-score for executive functions
324 (OS vs. DS: 3.89 ± 1.05 vs. 4.47 ± 0.84 ; $p=.071$; OS vs. preoperative baseline: $3.89 \pm$
325 1.05 vs. 4.63 ± 0.60 ; $p=.015$).

	Scores		Wilcoxon signed-rank test		
	Omnidirectional	Directional	Omnidirectional vs Directional		
	Mean \pm SD/ Median [min max]	Mean \pm SD/ Median [min max]	p-value	z-value	n
MDS-UPDRS I	11.16 \pm 8.49	11.00 \pm 5.94	0.909	-0.114	17
MDS-UPDRS II	18.16 \pm 9.32	19.06 \pm 9.19	0.568	-0.571	18
MDS-UPDRS III	28.63 \pm 12.91	32.42 \pm 15.07	0.121	-1.550	19
MDS-UPDRS IV	8.17 \pm 4.89	8.78 \pm 4.45	0.925	-0.095	17
VDR					
Task accuracy	0.70 \pm 0.29	0.69 \pm 0.23	1.000	0.000	17
Task reaction time	2.56 \pm 0.51	2.54 \pm 0.59	0.845	-0.196	18
Oddball accuracy	0.96 \pm 0.08	0.94 \pm 0.11	0.271	-1.100	18
Oddball reaction time	0.91 \pm 0.32	0.85 \pm 0.27	0.267	-1.111	18
SDR					
Task accuracy	0.25 \pm 0.12	0.22 \pm 0.09	0.355	-0.924	17
Task reaction time	1.83 \pm 0.64	1.71 \pm 0.53	0.918	-0.103	16
Oddball accuracy	0.64 \pm 0.26	0.57 \pm 0.26	0.265	-1.115	17
Oddball reaction time	1.09 \pm 0.35	1.01 \pm 0.33	0.469	-0.724	16
FoG-AC	11.47 \pm 13.02	12.80 \pm 13.80	0.129	-1.517	15
CAPSIT					
Steps	39.11 \pm 20.55	42.00 \pm 22.02	0.072	-1.801	17
Time (s)	27.44 \pm 23.74	31.82 \pm 34.04	0.142	-1.468	17
Freezing episodes	1.56 \pm 3.75	1.53 \pm 3.63	0.131	-1.511	17
MOCA	26.53 \pm 3.15	27.83 \pm 1.92	0.080	-1.753	17
Executive	3.89 \pm 1.05	4.47 \pm 0.84	0.071	-1.805	19
Naming	2.84 \pm 0.69	3.00 \pm 0.00	0.317	-1.000	18
Attention	5.58 \pm 0.69	5.44 \pm 0.86	0.206	-1.265	18
Language	2.44 \pm 0.62	2.32 \pm 0.82	0.366	-0.905	18
Abstraction	1.89 \pm 0.32	2.00 \pm 0.00	0.157	-1.414	18
Delayed Recall	3.95 \pm 1.31	4.37 \pm 0.83	0.323	-0.988	19
Orientation	5.95 \pm 0.23	6.00 \pm 0.00	0.317	-1.000	19
BDI	13.56 \pm 7.25	14.88 \pm 6.91	0.448	-0.758	17
AS	16.11 \pm 4.58	17.58 \pm 4.49	0.646	-0.406	16
DBS-IS	25.94 \pm 14.61	28.06 \pm 12.52	0.674	-0.421	17
LARS	-22.47 \pm 7.33	-20.61 \pm 10.14	0.275	-1.091	18
PDQ 39					
Mobility	19.22 \pm 10.73	21.13 \pm 8.16	0.380	-0.877	15
Activities of daily living	9.06 \pm 5.68	9.72 \pm 5.06	1.000	0.000	17
Emotions	8.06 \pm 4.56	9.00 \pm 4.04	0.318	-0.999	17
Stigma	3.50 \pm 3.24	4.39 \pm 2.43	0.304	-1.027	17
Social support	1.94 \pm 2.31	2.53 \pm 2.27	0.094	-1.672	17
Cognition	5.00 \pm 3.27	6.38 \pm 2.90	0.477	-0.711	15
Communication	4.06 \pm 3.42	4.53 \pm 2.74	0.832	-0.212	16
Bodily discomfort	5.11 \pm 2.61	5.35 \pm 2.34	0.640	-0.467	16

326

327 *Table 3: Six months after surgery, in the cross-over period (V4/5), there were no*
 328 *significant differences between OS and DS with regard to motor and non-motor*

329 *symptoms during the chronic evaluation (i.e., after 3-week stimulation blocks of each*
330 *condition).*

331 **Discussion**

332 This study determined the potential of directional stimulation steering (DS) with
333 segmented contacts to improve the therapeutic precision of STN-DBS. Specifically, and
334 in contrast to previous work, we investigated whether DS allowed for a more efficient
335 stimulation of the target structure by lowering the stimulation intensity required to
336 achieve the clinical benefit with regard to motor symptoms. For this purpose, the study
337 had unique methodological features: The optimal contacts were identified by conducting
338 the stimulation titration with small increments in stimulation intensity (0.2 mA steps) for
339 both OS and DS; the TEED was maintained between OS and DS for longer observation
340 periods beyond acute assessments in a cross-over design; thereby, also non-motor
341 symptoms, e.g., cognitive impairment, could be assessed. By that, this study revealed
342 that there were no significant differences between OS and DS with regard to all
343 outcome parameters, with 30% less stimulation intensity of the latter. Whether the more
344 focused stimulation of the target structure with DS will also achieve fewer side effects,
345 e.g., with regard to executive functions, needs to be investigated in confirmatory
346 studies, since this exploratory approach could potentially be affected by multiple
347 comparisons.

348 Currently, there are few systematic studies comparing directional STN-DBS to standard
349 omnidirectional stimulation which include intra- and extra-operative assessments. One
350 intraoperative study (14) demonstrated a larger therapeutic window with DS, i.e., an
351 increase of the distance between the clinical effect threshold (i.e., minimum stimulation
352 intensity to elicit a beneficial effect) and the side effect threshold (i.e., minimum
353 stimulation intensity to elicit side effects). However, another intraoperative study (13) did
354 not demonstrate any relevant increases of the therapeutic window with DS compared to
355 conventional OS. Two extraoperative studies (one retrospective, open-label pilot study
356 (16), and one prospective, randomized and double-blind study (15)) found an increase
357 in the side effect threshold, but no decrease in the clinical effect threshold (i.e.,
358 therapeutic current strength); while another extraoperative retrospective, open-label

359 case series showed a decrease also of the clinical effect threshold with directional
360 programming (48). However, the clinical evaluations in this latter study were conducted
361 with different step-sizes of the applied stimulation amplitudes, i.e., 0.5 mA for OS and
362 0.1-0.2 mA for DS, which considers the higher charge density of the latter, but may also
363 bias the findings with regard to the sensitivity for clinical effect and side effect threshold
364 detection. An accurate thresholding with the same amplitude step-sizes for both
365 stimulation conditions is an important prerequisite for detecting improved therapeutic
366 effectiveness of one approach or the other. Furthermore, relevant differences between
367 the various segmented stimulation directions could be found with regards to the side
368 effect threshold (16), but not with regard to the therapeutic effectiveness (14). Possible
369 reasons for these variable findings are: (i) different accuracies in titration of the
370 stimulation amplitude (in previous extraoperative studies, the systematic titration of the
371 stimulation amplitude was carried out in steps of 0.5 mA (16) or 1.0 mA (15), whereas
372 Pollo and colleagues (14) chose 0.1 mA steps for their intraoperative examinations); (ii)
373 stimulation effects were recorded clinically and on an ordinal scale (i.e. UPDRSIII) and
374 were therefore dependent on a subjective assessment of the symptoms and the
375 experience of the examiner.

376 The most comprehensive investigation to date is the prospective, randomized, double-
377 blind PROGRESS multicenter study (17). The primary endpoint was evaluated acutely
378 three months after initial programming by demonstrating that DS resulted in a wider
379 therapeutic window using DS (2.98 ± 1.38 mA) compared to OS (2.11 ± 1.33 mA).
380 Moreover, DS (1.11 ± 1.00 mA) could reduce the current required to achieve symptom
381 relief compared to OS (1.83 ± 1.52 mA) (17). As with previous studies, a systematic
382 evaluation of non-motor symptoms was missing, and unlike our study, the outcome was
383 based on subjective clinical assessments using the ordinal UPDRS scale only. Also, the
384 stimulation titration protocols were not reported in the study, and presumably varied
385 across centers. And finally, like all studies to date that have systematically assessed
386 directional STN-DBS, the TEED across stimulation conditions was not maintained for
387 longer periods. Moreover, the 3-months open-label observations had a fixed order (i.e.,
388 OS period always prior to the DS period).

389 The present study aimed to address some limitations of previous studies investigating
390 directional DBS. Namely, OS and DS were compared by complementing the subjective
391 clinical evaluation by an objective assessment of muscular rigidity using EMG;
392 furthermore, stimulation parameter titration was performed using small increments in the
393 current amplitudes for both stimulation conditions; and finally, TEED, and thereby
394 battery power consumption, was maintained for three weeks for each condition, when
395 comparing OS and DS.

396 In the present study, DS and OS had no significant differences with regard to motor
397 symptoms in both clinical and EMG-based measures, when controlling for the above-
398 mentioned confounding factors. However, OS had (non-significantly) better clinical
399 effects than DS on all motor and non-motor measures apart from the cognitive
400 evaluation (see below). These differences between OS and DS were more apparent in
401 the chronic (3 weeks) than in the acute (30 minutes) evaluation settings.

402 Specifically, the UPDRS III score (39.63 ± 12.92 in the Stim OFF condition) improved
403 with OS (30.00 ± 13.55 ; $p=.001$) and DS (30.72 ± 10.87 ; $p=.003$) in the acute
404 assessment. In the chronic setting, UPDRS III improved even further with OS ($28.63 \pm$
405 12.91), while it deteriorated with DS (32.42 ± 15.07); notably, the average difference
406 (28.63 ± 12.91 vs. 32.42 ± 15.07) between conditions crossed the 3.25-point threshold
407 for a minimal clinically important difference (MCID) of the UPDRS III (49), even though
408 this difference was not significant due to the large variability within each condition.

409 Similarly, FoG-AC (17.83 ± 15.05 in the Stim OFF condition) improved with both OS
410 (14.83 ± 13.66 ; $p=.021$) and DS (13.92 ± 13.32 ; $p=.024$) in the acute assessment, and
411 even further in the chronic setting (OS: 11.47 ± 13.02 ; DS: 12.80 ± 13.80).

412 These observations were complemented by the fact that in 3 of 19 patients, the
413 electrical energy of DS needed to be increased during the chronic/long-term period
414 above and beyond the estimated TEED to reach the therapeutic motor benefits of OS.
415 These findings indicate that long-term assessments are necessary to capture the overall
416 benefit of different programming approaches.

417 The cognitive long-term assessment revealed an exception and the only difference
418 between the stimulation conditions favoring DC; namely, DS led to (non-significantly)
419 higher MOCA scores, i.e., less cognitive impairment, as compared to OS (27.83 ± 1.92
420 vs. 26.53 ± 3.15 ; $p=.080$). Despite the small effect size, this observation warrants further
421 investigations in future due to different considerations: This finding was the only one in
422 favour of DS, and thereby in contrast to the above-mentioned overall trend of the other
423 motor and non-motor findings in favour of OS. Moreover, this MOCA change in PD
424 patients is not to be expected within the short six weeks evaluation period (50).
425 Furthermore, the observed effect was driven by a deterioration of the MOCA sub-score
426 for executive function (OS vs. DS: 3.89 ± 1.05 vs. 4.47 ± 0.84 ; $p=.071$; OS vs.
427 preoperative baseline: 3.89 ± 1.05 vs. 4.63 ± 0.60 ; $p=.015$), which was previously
428 shown to be particularly affected by STN-DBS (51).

429 This stimulation-induced impact on executive function may be explained by the different
430 volumes of tissue activated (VTA) by OS vs. DS. Specifically, computational modeling
431 suggested that TEED-balanced DS, i.e., applying about 30% less stimulation amplitude
432 with DS than OS (like in the present study), reduced the total VTA by 15% (28). This
433 reduced the coverage of the targeted and non-targeted volumes in the STN leading to
434 less motor benefits and less side effects regarding executive function, respectively.
435 However, these interpretations remain speculative since the clinical differences between
436 the OS and DS conditions did not reach statistical significance.

437 ***Limitations and considerations***

438 While we attempted to control as many conditions as possible to achieve an impartial
439 and highly systematic comparison between DS and OS, this study is not without
440 limitations. It must first be acknowledged that the sample size of our study is
441 comparable to other single center studies but far smaller than that of the multicenter
442 PROGRESS study. However, one advantage of our study is that each patient
443 underwent a consistent and highly scrutinous procedure for stimulation programing and
444 parameter titration using small current intensity increments for both stimulation
445 conditions.

446 Moreover, the EMG activity recorded in our study provided an objective measure, but
447 may have missed differences between conditions due to much variability between data
448 points caused by some variability of electrode placements across evaluations.
449 Nevertheless, the results are congruent with the standard subjective ordinal scale-
450 based evaluations in this study, e.g., the UPDRS III scores.

451 Finally, a very important consideration that is unique to this study is that the TEED was
452 maintained across the two stimulation conditions. This means that the current intensity
453 used for DS was always lower than for OS, and lower than its own side effect threshold.
454 While this did allow for an impartial comparison of the two conditions when taking into
455 consideration TEED and thus battery lifespan, it did not allow for the comparison of the
456 two conditions at each of their respective maximum current intensities, i.e., activated
457 VTA. The current findings, therefore, suggest that DS even below the maximum
458 tolerable settings can achieve similar therapeutic efficacy as OS, even though the OS
459 effects seemed (non-significantly) larger across measures. However, we are left with
460 the question of whether DS at the maximum possible current intensity may have
461 produced superior clinical benefits in our cohort compared to OS. Finally, the
462 observation periods of 3 weeks for each condition might have been too short to
463 delineate even larger differences between the conditions.

464 **Conclusions**

465 There were no significant differences between OS and DS with regard to motor and
466 non-motor outcome parameters when they were applied at the same TEED levels, i.e.,
467 with 30% less stimulation intensity of the latter. However, in some cases, the stimulation
468 intensity of DS needed to be increased above and beyond the TEED-estimated value to
469 reach the motor benefits of OS. Furthermore, OS scored (non-significantly) better than
470 DS in all motor and non-motor measures apart from the cognitive evaluation, where OS
471 led to a deterioration of executive functions.

472 Long-term observation periods beyond acute assessments are necessary to identify
473 differences in overall treatment benefit. Future confirmatory studies with larger sample
474 cohorts and longer follow-up periods need to investigate the potential outcome
475 differences of OS and DS with regard to motor and cognitive functions.

476

477

478 ***Credit authorship contribution statement***

479 Alireza Gharabaghi: Funding acquisition, Conceptualization, Project administration,
480 Writing – original draft.

481 Idil Cebi: Project administration, Investigation, Formal analysis, Writing – review &
482 editing.

483 Maximilian Scherer: Methodology, Investigation, Formal analysis, Writing – review &
484 editing.

485 Patrick Bookjans: Investigation, Formal analysis, Writing – review & editing.

486 Bastian Brunnett: Investigation, Formal analysis, Writing – review & editing.

487 Luka Milosevic: Investigation, Formal analysis, Methodology, Writing – original draft.

488 Daniel Weiss: Funding acquisition, Conceptualization, Writing – review & editing.

489

490 ***Funding***

491 This investigator-initiated trial was supported by Abbott / St. Jude Medical (SANTOP).
492 The funding had no impact on the study design, on the collection, analysis and
493 interpretation of data, on the writing of the report or on the decision to submit the article
494 for publication.

495 ***Acknowledgements***

496 A.G. was supported by the German Federal Ministry of Education and Research
497 (BMBF). M.S. was supported by the Alexander von Humboldt Foundation. D.W. was
498 supported by the German Research Council (WE5375/1-3) and the Michael J Fox
499 Foundation. We acknowledge support by the Open Access Publishing Fund of the
500 University of Tübingen.

501 ***Declarations of competing interests***

502 A.G. was supported by research grants from Medtronic, Abbott, Boston Scientific, all of
503 which were unrelated to this work. D. W. was supported by travel grants, speaker

504 honoraria and research grants from Abbott, Abbvie, Bial, Boston Scientific, Medtronic,
505 Kyowa Kirin, Stadapharm, all of which were unrelated to this work.

506 References

- 507 1. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, et al. A randomized trial
508 of deep-brain stimulation for Parkinson's disease. *N Engl J Med*. 2006;355(9):896-908.
- 509 2. Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, et al. Subthalamic nucleus
510 deep brain stimulation: summary and meta-analysis of outcomes. *Mov Disord*. 2006;21 Suppl
511 14:S290-304.
- 512 3. Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation
513 for Parkinson's disease with early motor complications. *N Engl J Med*. 2013;368(7):610-22.
- 514 4. Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, et al. Randomized trial of deep brain
515 stimulation for Parkinson disease: thirty-six-month outcomes. *Neurology*. 2012;79(1):55-65.
- 516 5. Lhommee E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, et al. Behavioural outcomes of
517 subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's
518 disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label
519 randomised trial. *Lancet Neurol*. 2018;17(3):223-31.
- 520 6. Weiss D, Volkmann J, Fasano A, Kuhn A, Krack P, Deuschl G. Changing Gears - DBS For
521 Dopaminergic Desensitization in Parkinson's Disease? *Ann Neurol*. 2021;90(5):699-710.
- 522 7. Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach WM, Krack P, et al. Cost-
523 effectiveness of neurostimulation in Parkinson's disease with early motor complications. *Mov*
524 *Disord*. 2016;31(8):1183-91.
- 525 8. Wodarg F, Herzog J, Reese R, Falk D, Pinsker MO, Steigerwald F, et al. Stimulation site within the
526 MRI-defined STN predicts postoperative motor outcome. *Mov Disord*. 2012;27(7):874-9.
- 527 9. Bari AA, Fasano A, Munhoz RP, Lozano AM. Improving outcomes of subthalamic nucleus deep
528 brain stimulation in Parkinson's disease. *Expert Rev Neurother*. 2015;15(10):1151-60.
- 529 10. Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H, et al. Long term effects of bilateral
530 subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's
531 disease. *J Neurol Neurosurg Psychiatry*. 2004;75(6):834-9.
- 532 11. Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, et al. Subthalamic
533 nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease
534 (NSTAPS study): a randomised controlled trial. *Lancet Neurol*. 2013;12(1):37-44.
- 535 12. Rolston JD, Englot DJ, Starr PA, Larson PS. An unexpectedly high rate of revisions and removals
536 in deep brain stimulation surgery: Analysis of multiple databases. *Parkinsonism Relat Disord*.
537 2016;33:72-7.
- 538 13. Contarino MF, Bour LJ, Verhagen R, Lourens MA, de Bie RM, van den Munckhof P, et al.
539 Directional steering: A novel approach to deep brain stimulation. *Neurology*. 2014;83(13):1163-
540 9.
- 541 14. Pollo C, Kaelin-Lang A, Oertel MF, Stieglitz L, Taub E, Fuhr P, et al. Directional deep brain
542 stimulation: an intraoperative double-blind pilot study. *Brain*. 2014;137(Pt 7):2015-26.
- 543 15. Dembek TA, Reker P, Visser-Vandewalle V, Wirths J, Treuer H, Klehr M, et al. Directional DBS
544 increases side-effect thresholds-A prospective, double-blind trial. *Mov Disord*.
545 2017;32(10):1380-8.
- 546 16. Steigerwald F, Muller L, Johannes S, Matthies C, Volkmann J. Directional deep brain stimulation
547 of the subthalamic nucleus: A pilot study using a novel neurostimulation device. *Mov Disord*.
548 2016;31(8):1240-3.
- 549 17. Schnitzler A, Mir P, Brodsky MA, Verhagen L, Groppa S, Alvarez R, et al. Directional Deep Brain
550 Stimulation for Parkinson's Disease: Results of an International Crossover Study With
551 Randomized, Double-Blind Primary Endpoint. *Neuromodulation*. 2022;25(6):817-28.

- 552 18. Rosahl SK, Gharabaghi A, Liebig T, Feste CD, Tatagiba M, Samii M. Skin markers for surgical
553 planning for intradural lesions of the thoracic spine. Technical note. *Surg Neurol.*
554 2002;58(5):346-8.
- 555 19. Southwell DG, Narvid JA, Martin AJ, Qasim SE, Starr PA, Larson PS. Comparison of Deep Brain
556 Stimulation Lead Targeting Accuracy and Procedure Duration between 1.5- and 3-Tesla
557 Interventional Magnetic Resonance Imaging Systems: An Initial 12-Month Experience. *Stereotact*
558 *Funct Neurosurg.* 2016;94(2):102-7.
- 559 20. Naros G, Grimm F, Weiss D, Gharabaghi A. Directional communication during movement
560 execution interferes with tremor in Parkinson's disease. *Mov Disord.* 2018;33(2):251-61.
- 561 21. Milosevic L, Scherer M, Cebi I, Guggenberger R, Machetanz K, Naros G, et al. Online Mapping
562 With the Deep Brain Stimulation Lead: A Novel Targeting Tool in Parkinson's Disease. *Mov*
563 *Disord.* 2020;35(9):1574-86.
- 564 22. Milian M, Luerding R, Ploppa A, Decker K, Psaras T, Tatagiba M, et al. "Imagine your neighbor
565 mows the lawn": a pilot study of psychological sequelae due to awake craniotomy: clinical
566 article. *J Neurosurg.* 2013;118(6):1288-95.
- 567 23. Weiss D, Breit S, Wachter T, Plewnia C, Gharabaghi A, Kruger R. Combined stimulation of the
568 substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait
569 disturbance in Parkinson's disease. *J Neurol.* 2011;258(6):1183-5.
- 570 24. Kramme J, Dembek TA, Treuer H, Dafsari HS, Barbe MT, Wirths J, et al. Potentials and Limitations
571 of Directional Deep Brain Stimulation: A Simulation Approach. *Stereotact Funct Neurosurg.*
572 2021;99(1):65-74.
- 573 25. Mishra A, Unadkat P, McBriar JD, Schulder M, Ramdhani RA. An Institutional Experience of
574 Directional Deep Brain Stimulation and a Review of the Literature. *Neuromodulation.* 2023.
- 575 26. Ramanathan PV, Salas-Vega S, Shenai MB. Directional Deep Brain Stimulation-A Step in the Right
576 Direction? A Systematic Review of the Clinical and Therapeutic Efficacy of Directional Deep Brain
577 Stimulation in Parkinson Disease. *World Neurosurg.* 2023;170:54-63 e1.
- 578 27. Merola A, Singh J, Reeves K, Changizi B, Goetz S, Rossi L, et al. New Frontiers for Deep Brain
579 Stimulation: Directionality, Sensing Technologies, Remote Programming, Robotic Stereotactic
580 Assistance, Asleep Procedures, and Connectomics. *Front Neurol.* 2021;12:694747.
- 581 28. Rebelo P, Green AL, Aziz TZ, Kent A, Schafer D, Venkatesan L, et al. Thalamic Directional Deep
582 Brain Stimulation for tremor: Spend less, get more. *Brain Stimul.* 2018;11(3):600-6.
- 583 29. Levin J, Krafczyk S, Valkovic P, Eggert T, Claassen J, Botzel K. Objective measurement of muscle
584 rigidity in Parkinsonian patients treated with subthalamic stimulation. *Mov Disord.*
585 2009;24(1):57-63.
- 586 30. Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson's
587 disease with deep brain stimulation. *Lancet Neurol.* 2012;11(5):429-42.
- 588 31. Foltynie T, Zrinzo L, Martinez-Torres I, Tripoliti E, Petersen E, Holl E, et al. MRI-guided STN DBS in
589 Parkinson's disease without microelectrode recording: efficacy and safety. *J Neurol Neurosurg*
590 *Psychiatry.* 2011;82(4):358-63.
- 591 32. Hutchison WD, Allan RJ, Opitz H, Levy R, Dostrovsky JO, Lang AE, et al. Neurophysiological
592 identification of the subthalamic nucleus in surgery for Parkinson's disease. *Ann Neurol.*
593 1998;44(4):622-8.
- 594 33. Koss AM, Alterman RL, Tagliati M, Shils JL. Calculating total electrical energy delivered by deep
595 brain stimulation systems. *Ann Neurol.* 2005;58(1):168; author reply -9.
- 596 34. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement
597 Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-
598 UPDRS): scale presentation and clinimetric testing results. *Mov Disord.* 2008;23(15):2129-70.

- 599 35. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical
600 interventional therapies in Parkinson's disease (CAPSIT-PD). *Mov Disord.* 1999;14(4):572-84.
- 601 36. Ziegler K, Schroeteler F, Ceballos-Baumann AO, Fietzek UM. A new rating instrument to assess
602 festination and freezing gait in Parkinsonian patients. *Mov Disord.* 2010;25(8):1012-8.
- 603 37. Hershey T, Craft S, Glauser TA, Hale S. Short-term and long-term memory in early temporal lobe
604 dysfunction. *Neuropsychology.* 1998;12(1):52-64.
- 605 38. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM. Cognitive impairments in early Parkinson's
606 disease are accompanied by reductions in activity in frontostriatal neural circuitry. *J Neurosci.*
607 2003;23(15):6351-6.
- 608 39. Kaufman DA, Bowers D, Okun MS, Van Patten R, Perlstein WM. Apathy, Novelty Processing, and
609 the P3 Potential in Parkinson's Disease. *Front Neurol.* 2016;7:95.
- 610 40. Mathis S, Neau JP, Pluchon C, Fargeau MN, Karolewicz S, Iljicsov A, et al. Apathy in Parkinson's
611 disease: an electrophysiological study. *Neurol Res Int.* 2014;2014:290513.
- 612 41. Vukelic M, Gharabaghi A. Self-regulation of circumscribed brain activity modulates spatially
613 selective and frequency specific connectivity of distributed resting state networks. *Front Behav*
614 *Neurosci.* 2015;9:181.
- 615 42. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and
616 application of a Parkinson's disease quality of life questionnaire and its associated measures. *J*
617 *Neurol.* 1998;245 Suppl 1:S10-4.
- 618 43. Beck A. T. SR. Manual for the Beck Depression Inventory. Psychological Corporation, San
619 Antonio, TX; 1987.
- 620 44. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal
621 Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr*
622 *Soc.* 2005;53(4):695-9.
- 623 45. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability,
624 validity, and clinical correlates of apathy in Parkinson's disease. *J Neuropsychiatry Clin Neurosci.*
625 1992;4(2):134-9.
- 626 46. Sockeel P, Dujardin K, Devos D, Deneve C, Destee A, Defebvre L. The Lille apathy rating scale
627 (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease.
628 *J Neurol Neurosurg Psychiatry.* 2006;77(5):579-84.
- 629 47. Maier F, Lewis CJ, Eggers C, Kuhn AA, Volkman J, et al. Development and validation of
630 the deep brain stimulation impairment scale (DBS-IS). *Parkinsonism Relat Disord.* 2017;36:69-75.
- 631 48. Rammo RA, Ozinga SJ, White A, Nagel SJ, Machado AG, Pallavaram S, et al. Directional
632 Stimulation in Parkinson's Disease and Essential Tremor: The Cleveland Clinic Experience.
633 *Neuromodulation.* 2022;25(6):829-35.
- 634 49. Horvath K, Aschermann Z, Acs P, Deli G, Janszky J, Komoly S, et al. Minimal clinically important
635 difference on the Motor Examination part of MDS-UPDRS. *Parkinsonism Relat Disord.*
636 2015;21(12):1421-6.
- 637 50. Lessig S, Nie D, Xu R, Corey-Bloom J. Changes on brief cognitive instruments over time in
638 Parkinson's disease. *Mov Disord.* 2012;27(9):1125-8.
- 639 51. Bucur M, Papagno C. Deep Brain Stimulation in Parkinson Disease: A Meta-analysis of the Long-
640 term Neuropsychological Outcomes. *Neuropsychol Rev.* 2023;33(2):307-46.

641